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AbstrACt
Introduction To establish pregnancy, the maternal 
immune system must adapt to tolerate the semiallogenic 
fetus. Less than optimal adaptation of the maternal 
immune system during (early) pregnancy is implicated in 
several complications of pregnancy. The development of 
effective immune modulation interventions as preventive 
or therapeutic strategies for pregnancy complications 
holds promise. Several studies sought to evaluate the 
safety and effectiveness of various approaches. However, 
a limitation is the high variability in clinical and immune 
outcomes that are reported. We, therefore, aim to develop 
a core outcome set for application to studies of immune 
modulation in pregnancy (COSIMPREG).
Methods and analysis We will use a stepwise approach 
to develop a COSIMPREG. First, we will perform a 
systematic review to identify reported outcomes. For 
this review, Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines will be followed. 
Second, we will use the Delphi method to develop a 
preliminary COSIMPREG. In three rounds, the outcomes of 
the systematic review will be scored. A panel comprising 
experts from relevant disciplines and diverse geographical 
locations will be assembled until a sufficient quality of 
the panel is reached. We will use predefined decision 
rules for outcomes. After each round outcomes, including 
scores, will be returned to the panel for further refinement. 
The outcomes not excluded after the third round will be 
taken to a consensus meeting. In this meeting, experts 
from all relevant disciplines will discuss and finalise the 
COSIMPREG.
Ethics and dissemination For this study ethical approval 
is not required. The systematic review will be published 
in an appropriate open access reproductive immunology 
journal. Once the COSIMPREG is finalised, it will be 
published in an open access reproductive immunology 
journal, and disseminated at appropriate international 
meetings, as well as through relevant research and 
scientific societies. Experts involved in the Delphi study 
will be asked to give informed consent.
IntroduCtIon 
The maternal immune response is instru-
mental in pregnancy health.1 Failure of the 
immune response to adapt and respond 
correctly to conception and embryo implan-
tation is associated with, and likely plays a 
causal role in, many complications of preg-
nancy.2 During early pregnancy the maternal 
immune system must adapt to tolerate the 
fetus and placenta, both of which express 
paternal (foreign) as well as maternal histo-
compatibility antigens. Maladaptation of 
the maternal immune system is associated 
with common complications of pregnancy 
including preterm birth, pre-eclampsia, fetal 
growth restriction, and recurrent miscar-
riages.2–4 Various approaches to immune 
modulation have been used for several indi-
cations in attempts to improve pregnancy 
outcome.5 These approaches include drugs 
which have effects on the immune system, 
but also on other pathways. For example, 
a commonly used therapy is acetylsali-
cylic acid (aspirin), which is widely used to 
prevent pre-eclampsia.6 In other reproduc-
tive disorders, such as recurrent miscarriage, 
interventions including paternal leucocyte 
immunisation, progesterone, and steroids 
have been used, mostly with no demon-
strable benefit.5 This could be explained by 
the fact that reproductive disorders, such as 
recurrent miscarriage, have a multifactorial 
strengths and limitations of this study
 ► The Delphi procedure involves experts from all rele-
vant stakeholder groups including patients.
 ► The Delphi procedure allows unbiased contributions 
and is anonymous.
 ► The systematic review and input of topic experts will 
assemble and synthesise evidence from a broad, 
inclusive base.
 ► This protocol covers a topic which holds enormous 
potential for future reproductive medicine.
 ► The intention is to publish the results in open access 
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pathogenesis, and that developing a successful immune 
modulator depends on selecting appropriate patient 
groups.
There is a reasonable prospect that given advances in 
other disease conditions such as oncology7 and autoim-
mune disease,8 9 more targeted and effective immune-mod-
ulating therapeutic options will emerge for reproduction 
medicine. Although several preclinical/animal studies 
show promising results,10–13 these options must now be 
tailored to achieve targeted, safe immunotherapy both 
as prevention and therapy for pregnancy complications. 
Moreover, since a range of factors, including non-immune 
related, is implicated in pregnancy complications,14 selec-
tion of the right patients will be essential for the success 
of therapy.5 15
In the current literature, there is high variability in 
the reported clinical outcomes and immunological 
parameters measured.15 This variability hampers proper 
comparison across studies and harmonisation of data sets. 
Therefore, the objective of this study is to develop a core 
outcome set for studies investigating immune modulation 
in pregnancy (COSIMPREG).16 17 Although immunolog-
ical studies in pregnancy are usually condition based with 
associated condition-specific outcomes, the COS devel-
oped in the current study will comprise the fundamental 
outcomes which are considered essential for reporting 
in all reproductive immunology studies. Specific COSs 
have now been developed for multiple clinical condi-
tions, with demonstrable benefit for advancing medical 
care.18 In cases where immune modulation is studied in a 
specific clinical condition, then both COS outcomes for 
the clinical condition and the immune modulation will 
be collected, and most likely there will be overlap of core 
outcomes across conditions.
Aim
The aim of this study is to develop a COSIMPREG. We aim 
to develop COSs for studies both in humans and animals 
that will be reported separately. We will obtain these COSs 
by consensus among a group of relevant experts using a 




To develop a COSIMPREG, a stepwise approach will be 
used19:
1. Perform a systematic review to identify reported out-
comes for immune modulation already in use.
2. Use a Delphi procedure to develop a preliminary COS 
with input from the systematic review and experts.
3. Organise a consensus meeting to discuss and finalise 
the COSIMPREG.
4. Disseminate and promote application of the final 
COSIMPREG.
This study commenced in December 2017, with an 
expected completion date of December 2019. The study 
is registered at the Comet Initiative: http://www. comet- 
initiative. org/ studies/ details/ 1004? result= true.
Patient and public involvement
Patient and public were not involved in the develop-
ment of this protocol. However, they will be involved and 
included within the Delphi procedure as expert group. 
And they will participate in the consensus meeting.
Perform a systematic review to identify reported outcomes for 
immune modulation already in use
The aim of the systematic review is to identify all 
outcomes that have been used to date in studies reporting 
on immune modulation in pregnancy. A secondary aim 
of this review is to identify potential experts for the 
Delphi panels. The review will be conducted according 
to Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines,20 and will be 
published separately. The review will include all studies, 
human as well as animal, investigating immune modu-
lation either as therapy or prevention, with the goal 
of improving pregnancy outcome. A comprehensive 
search will be conducted using the databases of PubMed, 
Embase and Cochrane Central Register of Controlled 
Trials. The search strategy will be different for human 
and animal studies. We will use free-text words and index 
terms (Medical Subject Headings (MeSH) for PubMed 
and Emtree for Embase). See table 1 for the preliminary 
Medline search strategies for human and animal studies. 
We will perform the literature search early March 2018. 
If the selection process extends beyond 6 months, the 
search will be updated to cover the interim period. No 
language or date restriction will be applied.
In order to identify all reported outcomes, we aim to 
include: (1) randomised clinical trials, open label clinical 
trials and cohort studies reporting on (2) immune therapy 
or other interventions targeting the immune response, in 
(3) pregnant human or animal subjects studying (4) the 
preventive or therapeutic effect on an adverse reproduc-
tive outcome.
Studies will not be included when they do not meet the 
inclusion criteria, for example: (1) pregnancy outcome 
reported as secondary outcome; (2) case reports, reviews 
and expert opinions.
Two reviewers (JRP and FH) will independently screen 
titles and abstracts of all citations in order to exclude 
all overtly irrelevant papers. One of the members of the 
review team (FH) is not involved in obstetric research, and 
will therefore be unaware of author and journal creden-
tials. Consensus on inclusion will be reached when: (1) 
both reviewers include a study, (2) agreement is reached 
after discussion in the case of differing opinions or (3) a 
third reviewer (SJG) is consulted in the case of persistent 
disagreement. For potentially relevant papers, the full 
text will be retrieved and studied in detail, to determine 
whether the inclusion criteria are met. In case of disagree-
ment, consensus between the reviewers will be reached 
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a third reviewer (SJG). To search for additional studies, 
reference lists of all included studies and relevant reviews 
will be checked, conference abstracts will be screened and 
published protocols without published follow-up data will 
be identified. If necessary, authors will be contacted.
Two authors (JRP and FH) will independently extract 
data from the included studies. Data will be extracted on 
the year of study, study design, study size, study popula-
tion, human/animal study, reported outcome(s) and 
authors. The reported outcomes in the included studies 
will first be summarised into human and animal studies, 
and thereafter into four categories, namely: maternal clin-
ical outcomes, fetal clinical outcomes, maternal immune 
parameters and fetal immune parameters. Furthermore, 
the above categories will be displayed for both preventive 
and therapeutic immune modulation interventions. The 
study outcome will have no influence on the extraction 
of the reported outcomes and parameters. Overlapping 
outcomes will be collated and reported under a covering 
term. For each reported outcome the number of times 
it is reported (absolute and relative) in studies will be 
shown. This scoring will also be done in the categories 
mentioned earlier. References will be organised using 
RefWorks. Data will be collected, entered in a predefined 
fact sheet and analysed using Microsoft Excel.
Since we aim to include all relevant outcomes and 
parameters reported to date and we will not discriminate 
on efficacy of intervention, the included studies will not 
be assessed regarding their risk of bias, nor will they be 
graded.
The protocol for the systematic review is not eligible for 
registration at Prospero as it has no direct health-related 
outcomes. JRP will be the guarantor of this review. JRP 
and FH are responsible for selection of studies for inclu-
sion and for data extraction. SJG will be consulted in case 
of disagreement. For the systematic review, there are no 
sources of financial support.
The findings of this systematic review will serve three 
purposes. First, in order to disseminate the results, it will 
be published in an open access peer-reviewed journal 
according to PRISMA guidelines.20 Second, the results 
will be used for the Delphi procedure in order to develop 
a COSIMPREG. Third, the extracted data regarding 
authors will help to identify potential experts for the 
Delphi procedure.
use a delphi procedure to develop a preliminary Cos with 
input from the systematic review and experts
To develop a preliminary COS for immune modulation 
studies in pregnancy, we will use Delphi methodology. 
In general, the aim of the Delphi method is to obtain 
consensus on a subject and to develop new knowledge, 
and this has been applied previously to COS develop-
ment.16 21 In the Delphi process, structured statements 
are scored by experts on relevance, then these statements 
are returned to the experts with scores at individual and 
discipline group level, and this process is repeated until 
consensus is reached. On average, Delphi procedures 
are reported to require three iterative rounds.21 Since 
we plan to reach final consensus by adding a consensus 
meeting at the completion of the Delphi procedure, 
three rounds of Delphi procedure are expected to be 
sufficient. All outcomes not excluded through the three 
Delphi rounds will be taken into the consensus meeting 
for final approval.
For the Delphi procedure, we will take an inclusive 
approach and cast a wide net to assemble several panels 
comprising experts from different professional disci-
plines, together with a patient/consumer group. To 
be included on a professional expert panel, members 
should have worked at least 5 years within their field and/
or should have recent publications related to immune 
modulation in pregnancy, or have a well-known status 
in a relevant field, and should have adequate English 
language skills. Experts in obstetrics, paediatrics, labo-
ratory based and clinical immunology, reproduction 
science, and midwifery will be included on the expert 
panels. To ensure that all panels have sufficient geograph-
ical distribution and to prevent bias, experts will be 
Table 1 Search strategy
#1 pre-eclampsi*[tiab] OR 
preeclampsi*[tiab] OR 
miscarriage*[tiab] OR pregnancy 
loss*[tiab] OR abort*[tiab] OR pre-
term[tiab] OR preterm[tiab] OR growth 
restrict*[tiab] OR pregnancy fail*[tiab] 
OR fetal loss* [tiab] OR infertile* [tiab]
#2 ‘immunoproteins’[Mesh] 
OR ‘cytokines’[Mesh] OR 
‘immunology’ [Subheading] 
OR immunomodulation[tiab] 
OR immune modulation[tiab] 
OR immunotherapy[tiab] OR 
‘immunomodulation’[Mesh]
#3 randomized controlled trial [pt] 
OR controlled clinical trial [pt] OR 
randomized [tiab] OR placebo [tiab] 
OR drug therapy [sh] OR randomly 
[tiab] OR trial [tiab] OR groups [tiab]))
#4 animal*[tiab] OR mice[tiab] OR 
mouse[tiab] OR rat[tiab] OR 
rats[tiab] OR pig[tiab] OR pigs[tiab]
OR sheep[tiab] OR goat*[tiab] OR 
lamb[tiab] OR lambs[tiab]
#5 improve*[Title] OR outcome*[Title] OR 
loss*[Title] OR treatment*[Title] OR 
decreas*[Title] OR failure*[Title] OR 
promot*[Title] OR impair*[Title] OR 
prevent*[Title] OR induc*[Title] OR 
restor*[Title] OR rebalanc*[Title]
#6 #1 AND #2 AND #3 NOT #4 Human studies
#7 #1 AND #2 AND #4 AND #5 Animal studies
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identified and selected through a range of processes, with 
a goal to include at least 100 relevant participants. First, 
potential experts involved in immune-modulating studies 
will be identified through the systematic review. This will 
identify potential experts with >5 years of work in this field 
and with relevant recent publications. Second, we will ask 
potential panel members to identify other experts and to 
provide names of other relevant experts (see below). We 
will ask experts specifically to nominate potential experts 
in South America, Africa and Asia-Oceania as these are 
regions that have been under-represented in previous 
Delphi procedures with an obstetric focus.22 23
Regarding the patient/consumer group selection the 
procedure is slightly different. We will invite patient 
and consumer organisations from a range of countries 
as above to become involved and to nominate appro-
priate individuals. To ensure geographical diversity in the 
Delphi procedure, we will include at least 10 experts on 
each panel (at least 10 paediatricians, at least 10 patients, 
etc).
As the use of medication or other interventions during 
pregnancy is dependent on the motivation and under-
standing of pregnant women, panels will include both 
healthy pregnant women and women who have expe-
rienced adverse outcomes that might reasonably have 
qualified for prevention or treatment with immune 
modulation. Women with a history of recurrent miscar-
riage, preterm birth, fetal growth restriction and/or 
pre-eclampsia, all complications of pregnancy for which 
immune modulation is considered as holding promise, 
will be eligible. To be included within a patient/consumer 
subpanel, women must have adequate English language 
skills.
Candidate expert and lay participants will be invited 
to participate in the Delphi procedure by email in which 
we will explain the background and goals of the study. 
Lay participants will be accessed through patient and 
consumer organisations (eg, the Dutch pre-eclampsia/
Hellp foundation/March of Dimes/Perinatal Society of 
Australia New Zealand) and invitational posters at partic-
ipating centres distributed around the world.
In the explanatory email, we will use written text 
supported by a video explaining the need for a set of core 
outcomes in reproductive immunology, and information 
on the time commitment and schedule for each Delphi 
round. The email will also contain a link to accept the 
invitation, to provide informed consent and to register in 
the software. Nominated experts will be invited to provide 
the names of other relevant experts who meet the inclu-
sion criteria, and reasonably should be invited to partic-
ipate to achieve optimal inclusion. Participants will be 
asked to not personally contact other potential experts 
and to not discuss the Delphi procedure, to ensure unbi-
ased input. Responses to the Delphi procedure will be 
semianonymised, such that participants are aware of 
their fellow panel members but not of their individual 
responses. Results returned will include individual expert 
responses as well as responses on a panel group level.
As not all different panels will include experts in animal 
studies and since we aim to develop two separate COS 
documents for animal and human studies, only the repro-
ductive science and immunology panels will be able to 
contribute to assembling the animal COS.
We anticipate a three-round Delphi procedure to reach 
consensus on the shortlist of core outcomes. The aim of 
the Delphi procedure is to eliminate all outcomes that 
are not fundamental or essential. Experts can only be 
part of a subsequent round if they complete the former 
one. In each round, the participants will receive an email 
with a summary of the response rates and results to date 
and a link to the next questionnaire. Each round will 
take approximately 3 weeks. Reminders will be sent to 
the respondents who have not yet responded, and 2 days 
before the deadline a final reminder will be sent.
First Delphi round
In the first round, an initial assessment of the relevance 
of possible outcomes, derived from the systematic review, 
will be made. Panel members will be asked to score 
the importance of outcomes on a 9-point Likert scale, 
following the Core Outcome Measures in Effectiveness 
Trials (COMET) advice.19 Items will be ranked and those 
with a median of at least 7 when a Likert of 9 is used will 
progress to the next round. To ensure a complete set of 
outcomes using the input of topic experts and patients/
consumers, participants will be asked to ‘rescue’ any 
outcome missed by the panel’s ranked list of outcomes 
and which they consider as a core outcome.
Second round
In the second round, the response rate for each panel 
and the overall response rate will be reported. All 
outcomes reaching the cut-off threshold from round 1 
will be presented again plus outcomes put forward for 
rescue by at least two participants. For each outcome, the 
scoring of round 1 will be presented at three levels: (1) 
at the participants’ individual level; (2) at the level of the 
expert subpanel and (3) at the level of the other expert 
panels. These results will be presented graphically in the 
form of a histogram (as generated by DelphiManager). 
Panel members’ own individual responses can then be 
compared against the score of their respective subpanel, 
and against the score of other subpanels. Participants will 
be asked to rate the importance of all outcomes again, 
but now with the knowledge of the scores in round 1. We 
will again underline in the explanatory text the aim of the 
study, namely to identify fundamental/essential outcomes 
to be reported as a minimum set in each study. It will be 
essential to not be excessively inclusive, in order that a 
manageable COS is delivered. We will emphasise that for 
every future reproductive immunology study this will be 
a minimum outcome set, and that additional outcomes 
relevant to individual studies can always be added. 
Furthermore, in this round we poll the panel members 
for availability to join the consensus meeting as a satellite 
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Third round
In round 3, outcomes will not be taken forward from 
the previous round if more than 70% of the total panel 
judged the outcome as not essential (scores 1–3 on 
9-point Likert scale) and less than 15% of experts regard 
this same outcome as important (score ≥7 on 9-point 
Likert scale). All the other outcomes will be presented 
in round 3.
A preliminary list of outcomes for the consensus 
meeting will be assembled. To that end, the outcomes 
retained after round 2 will be presented to the partici-
pants. The outcomes will be presented in similar way as in 
round 2. The reproductive scientists and immunologists 
will also receive a preliminary list of animal studies core 
outcomes.
After the third round, all outcomes having a score 
≥7 on the 9-point Likert scale in at least 70% of the partic-
ipants will be taken forward into the consensus meeting 
as potential COS. Outcomes with more than 70% of the 
participants judged as less important (score 1–3 on 9-point 
Likert scale) and less than 15% as important (score ≥7 on 
9-point Likert scale) will be excluded. Furthermore, the 
outcomes not regarded as essential for the COS and also 
not excluded will be presented at the consensus meeting 
for further consensus voting.
organise a consensus meeting to discuss and finalise the 
CosIMPrEG
To finalise the COSIMPREG, we will organise a consensus 
meeting as a satellite event to an international conference 
in 2019, most likely to one of the following meetings: 
Society of Reproductive Investigation, annual meeting 
of American Society of Reproductive Immunology or 
International Society for Immunology of Reproduction. 
This consensus meeting will be divided into a clinical 
consensus meeting (involving all experts in the human 
COS) and an animal consensus meeting (involving the 
reproductive scientists and immunologists only). The 
Delphi process is expected to take 12 months with final 
outcome disseminated in 2019. Within this consensus 
meeting, we aim to have members of each stakeholder 
group present in person. A full day meeting, with an open 
and collaborative character, is proposed with an objec-
tive facilitator who will actively encourage equal input 
of all participants and will prevent skewing by strong 
voices or dominance using nominal group techniques. 
All outcomes still present after round 3 (of either Likert, 
so added by rescue) will be presented at the consensus 
meeting.
to implement the CosIMPrEG
After the COSIMPREG is finalised, their uptake and 
application in studies reporting on immune modulation 
in pregnancy will be stimulated by publication of both the 
human and animal COS in an open access, peer-reviewed 
reproductive immunology journal. Further, dissemina-
tion will also be through presentations at appropriate 
international meetings, through relevant research and 
scientific societies, and through relevant journals and 
electronic media channels.
EthICs And dIssEMInAtIon
For the dissemination of the COS, we will use a range of 
different strategies to maximise awareness and encourage 
uptake. We will disseminate all possible outcome measures 
as a systematic review, and publish this in a peer-reviewed 
reproductive immunology or methodology journal. Then 
after finalising the COSIMPREG, we will disseminate it 
through different channels. First, we will publish the COS 
in a peer-reviewed reproductive immunology journal. 
Second, we will disseminate the COS at appropriate inter-
national meetings, such as reproductive immunology 
and reproductive sciences meetings. We will furthermore 
discuss it with patient/consumer organisations with an 
emphasis on relevance to pregnant women. We will also 
disseminate the COS through scientific societies and 
appropriate electronic media.
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